Metabolic syndrome management

Bibliography

• ALEXANDER CM, LANDSMAN PB, TEUTSCH SM et al.: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes (2003) 52:1210-1214.
   PubMed Web of Science ®Google Scholar
• ALBERTI KG, ZIMMET PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet. Med. (1998) 15:539-553.
   Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486.
   PubMed Web of Science ®Google Scholar
• EINHORN D, REAVEN GM, COBIN RH et al.: American college of endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. (2003) 9:237-252.
   PubMedGoogle Scholar
• ALBERTI KG, ZIMMET P, SHAW J: Metabolic syndrome – a new world-wide definition. A consensus statement from the international diabetes federation. Diabetic Med. (2006) 23(5):469-480.
   PubMed Web of Science ®Google Scholar
• MEIGS JB, WILSON PW, NATHAN DM, D'AGOSTINO RB, WILLIAMS K, HAFFNER DM: Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes (2003) 52:2160-2167.
   PubMed Web of Science ®Google Scholar
• PARK YW, ZHU S, PALANIAPPAN L et al.: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988 – 1994. Arch. Intern. Med. (2003) 163:427.
   PubMed Web of Science ®Google Scholar
• BASSUK SS, MANSON JE: Epidemiological evidence for the role of physical activity in reducing risk of Type 2 diabetes and cardiovascular disease. J. Appl. Physiol. (2005) 99:1193-1204.
   PubMed Web of Science ®Google Scholar
• CAMPBELL KL, MCTIERNAN A: Exercise and biomarkers for cancer prevention studies. J. Nutr. (2007) 137:S161-S169.
   PubMed Web of Science ®Google Scholar
• KRAUS WE, HOUMARD JA, DUSCHA BD et al.: Effects of the amount and intensity of exercise on plasma lipoproteins. N. Engl. J. Med. (2002) 347(19):1483-1492.
   PubMed Web of Science ®Google Scholar
• KLEIN BE, KLEIN R, LEE KE: Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care (2002) 25:1790-1794.
   PubMed Web of Science ®Google Scholar
• FREEMAN DJ, NORRIE J, SATTAR N et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation (2001) 103:357.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, BURING JE, COOK NR, RAFAI N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation (2003) 107:391.
   PubMed Web of Science ®Google Scholar
• RUTTER MK, MEIGS JB, SULLIVAN LM et al.: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation (2004) 110:380.
   PubMed Web of Science ®Google Scholar
• FESTA A, D'AGOSTINO R, TRACY RP, HAFFNER SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of Type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 51:1131.
   PubMed Web of Science ®Google Scholar
• HOTAMISLIGIL GS: Adipose expression of TNF: direct role in obesity-linked insulin resistance. Science (1993) 259:87-91.
   PubMed Web of Science ®Google Scholar
• PRADHAN AD, MANSON JE, RIFAI N et al.: C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA (2001) 286:327.
   PubMed Web of Science ®Google Scholar
• DEVARAJ S, XU DY, JIALAL I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation (2003) 107(3):398-404.
   PubMed Web of Science ®Google Scholar
• PICKUP JC, MATTOCK MB, CHUSNEY GD et al.: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome. Diabetologia (1997) 40:1286-1292.
   PubMed Web of Science ®Google Scholar
• MATSUZAWA Y, FUNASHI T, KIHAR S, SHIMOMURA I: Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. (2004) 24:29-33.
   PubMed Web of Science ®Google Scholar
• FESTA A, D'AGOSTINO R, HOWARD G et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation (2000) 102:42-47.
   PubMed Web of Science ®Google Scholar
• ANDERSEN RE, WADDEN TA, BARTLETT SJ, ZEMEL B, VERDE TJ, FRANCKOWIAK SC: Effects of lifestyle activity versus structured aerobic exercise in obese women: a randomized trial. JAMA (1999) 281(4):335-340.
   PubMed Web of Science ®Google Scholar
• WING RR, HILL JO: Successful weight loss maintenance. Annu. Rev. Nutr. (2001) 21:323-341.
   PubMed Web of Science ®Google Scholar
• NATIONAL INSTITUTE OF HEALTH: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. Bethesda MD. National Heart, Lung, and Blood Institute (1998):NIH Publication #98-4083.
   Google Scholar
• SUMMERS LK, FIELDING BA, BRADSHAW HA et al.: Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. Diabetologia (2002) 45:369-377.
   PubMed Web of Science ®Google Scholar
• PARILLO M, RIVELLESE AA, CIARDULLO AV et al.: A high-monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients. Metabolism (1992) 41:1373-1378.
   PubMed Web of Science ®Google Scholar
• NETTLESON J, KATZ R: n-3 long-chain polyunsaturated fatty acids in Type 2 diabetes: a review. J. Am. Dietetic Assoc. (2005) 105: 428.
   PubMedGoogle Scholar
• SIRTORI CR, CREPALDI G, MANZATO E et al.: One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alteration. Atherosclerosis (1998) 137:419-427.
   PubMed Web of Science ®Google Scholar
• MONTORI VM, FARMER A, WOLLAN PC, DINNEEN SF: Fish oil supplementation in Type 2 diabetes. A quantitative systematic review. Diabetes Care (2000) 23:1407-1415.
   PubMed Web of Science ®Google Scholar
• BAO DQ, MORI TA, BURKE V, PUDDEY IB, BEILIN LJ: Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension (1998) 32:710-717.
   PubMed Web of Science ®Google Scholar
• THIES F, MILES EA, NEBE-VON-CARON G et al.: Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. Lipids (2001) 36:1183-1193.
   PubMed Web of Science ®Google Scholar
• ERKKILA AT, LICHTENSTEIN AH, MOZAFFARIAN D, HERRINGTON DM: Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am. J. Clin. Nutr. (2004) 80:626-632.
   PubMed Web of Science ®Google Scholar
• SAMAHA FF, IQBAL N, SESHADRI P et al.: Low carbohydrate as compared to low fat diet in severe obesity. N. Engl. J. Med. (2003) 348:2074-2081.
   PubMed Web of Science ®Google Scholar
• EBBELING CB, LEIDIG MM, FELDMAN HA, LOVESKY MM, LUDWIG DS: Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA (2007) 297(19):2092-2102.
   PubMed Web of Science ®Google Scholar
• APPEL LJ, MOORE TJ, OBARZANEK E et al.: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. (1997) 336:1117-1124.
   PubMed Web of Science ®Google Scholar
• SACKS FM, SVETKEY LP, VOLLMER WM et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med. (2001) 344:3-10.
   PubMed Web of Science ®Google Scholar
• MILLER ER, ERLINGER TP, APPEL LJ: The effects of macronutrients on blood pressure and lipids: an overview of the DASH and OmniHeart trials. Curr. Atheroscler. Rep. (2006) 8:460-465.
   PubMedGoogle Scholar
• ESPOSITO L, MARFELLA R, CIOTOLA M et al.: Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA (2004) 292:1440.
   PubMed Web of Science ®Google Scholar
• KLEIN S, SHEARD NF, PI-SUNYER X et al.: American diabetes association, North American association for the study of obesity, American society for clinical nutrition: weight management through lifestyle modification for the prevention and management of Type 2 diabetes: rationale and strategies. Diabetes Care (2004) 27:2067-2073.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN COLLEGE OF SPORTS MEDICINE: Physical activity and public health: a recommendation from the centers for disease control and prevention and the American college of sports medicine. JAMA (1995) 273:402-407.
   Google Scholar
• TASK FORCE ON COMMUNITY PREVENTIVE SERVICES: Increasing physical activity: a report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm. Rep. (2001) 50:1-14.
   Google Scholar
• THOMPSON PD, BUCHNER D, PINA IL et al.; AMERICAN HEART ASSOCIATION COUNCIL ON CLINICAL CARDIOLOGY SUBCOMMITTEE ON EXERCISE, REHABILITATION, AND PREVENTION, AMERICAN HEART ASSOCIATION COUNCIL ON NUTRITION, PHYSICAL ACTIVITY, AND METABOLISM SUBCOMMITTEE ON PHYSICAL ACTIVITY: Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation (2003) 107:3109-3116.
   PubMed Web of Science ®Google Scholar
• COUILLARD C, DESPRES JP, LAMARCHE B et al.: Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the health, risk factors, exercise training and genetics (HERITAGE) family study. Arterioscler. Thromb. Vasc. Biol. (2001) 21(7):1226-1232.
   PubMed Web of Science ®Google Scholar
• KODAMA S, TANAKA S, SAITO K et al.: Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol. Arch. Intern. Med. (2007) 167:999-1008.
   PubMed Web of Science ®Google Scholar
• THE DIABETES PREVENTION PROGRAM (DPP) RESEARCH GROUP: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. (2002) 346:393-403.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352(9131):854-865.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352(9131):837-853.
   Google Scholar
• CHIASSON JL, JOSSE RG, GOMIS R et al.; STOP-NIDDM TRIAL RESEARCH GROUP: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 290(4):486-494.
   PubMed Web of Science ®Google Scholar
• THE DREAM (DIABETES REDUCTION ASSESSMENT WITH RAMIPRIL AND ROSIGLITAZONE MEDICATION) TRIAL INVESTIGATORS: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet (2006) 368:1039.
   Google Scholar
• SHADAD S, JENSEN MD: Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care (2003) 26:3148-3152.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM, GREENBERG AS, WESTON WM, CHEN H, WILLIAMS K, FREED MI: Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation (2002) 106:679-684.
   PubMed Web of Science ®Google Scholar
• SATOH N, OGAWA Y, USUI T et al.: Antiatherogenic effect of pioglitazone in Type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care (2003) 26:2493-2499.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE, DOLE JF, PATWARDHAN R, RAPPAPORT EB, FREED MI: Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. (2001) 86:280-288.
   PubMed Web of Science ®Google Scholar
• DORMANDY JA, CHARBONNEL B, ECKLAND DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomized controlled trial. Lancet (2005) 366:1279-1289.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, WOLSKI K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) 356:1-14.
   PubMed Web of Science ®Google Scholar
• HOME PD, POCOCK SJ, BECK-NIELSEN H et al.: Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N. Engl. J. Med. (2007).
   PubMed Web of Science ®Google Scholar
• RIZZA R, HENRY R, KAHN R: Commentary on the results and clinical implications of the PROactive study. Clin. Diabetes (2006) 24(2):66-68.
   Google Scholar
• SKYLER S: PROactive: a sad tale of inappropriate analysis and unjustified interpretation Clin. Diabetes (2006) 24(2):63-65.
   Google Scholar
• MAZZONE T, MEYER PM, FEINSTEIN SB et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes. A randomized trial. JAMA (2006) 296:2572-2581.
   PubMed Web of Science ®Google Scholar
• MARROQUIN OC, KIP KE, KELLEY DE et al.: Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation (2004) 109:714.
   PubMed Web of Science ®Google Scholar
• PYORALA K, BALLANTYNE CM, GUMBINER B et al.: Reduction of cardiovascular events by simvastatin in non-diabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care (2004) 27:1735.
   PubMed Web of Science ®Google Scholar
• BALLANTYNE CM, OLSSON AG, COOK TJ et al.: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation (2001) 104:3046.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. (1998) 81(4A):B18-B25.
   PubMed Web of Science ®Google Scholar
• REAVEN GM, LERNER R, STERN M, FARQUHAR JW: Role of insulin in endogenous hypertriglyceridemia. J. Clin. Invest. (1967) 46:1756-1767.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN T, ABBASI F, CHEAL K, CHU J, LAMENDOLA C, REAVEN G: Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. (2003) 139(10):802-809.
   PubMed Web of Science ®Google Scholar
• SUMNER AE, FINLEY KB, GENOVESE DJ, CRIQUI MH, BOSTON RC: Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch. Intern. Med. (2005) 165(12):1395-1400.
   PubMedGoogle Scholar
• FRUCHART JC, DURIEZ P, STAELS B: Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. (1999) 10(3):245-257.
   PubMed Web of Science ®Google Scholar
• BARTER P: Antiatherogenic properties of fibrates. Arterioscler. Thromb. Vasc. Biol. (2005) 25(6):1095-1096.
   PubMed Web of Science ®Google Scholar
• PASTERNAK RC, SMITH SC, BAIREY-MERZ CN, GRUNDY SM, CLEEMAN JI, LENFANT C: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol. (2002) 40:567-572.
   PubMed Web of Science ®Google Scholar
• PRUEKSARITANONT T, TANG C, QIU Y, MU L, SUBRAMANIAN R, LIN JH: Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. (2002) 30(11):1280-1287.
   PubMed Web of Science ®Google Scholar
• MANNINEN V, ELO MO, FRICK MH et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki heart study. JAMA (1988) 260:641-651.
   PubMed Web of Science ®Google Scholar
• MANNINEN V, TENKANEN L, KOSKINEN P et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study. Implications for treatment. Circulation (1992) 85:37-45.
   PubMed Web of Science ®Google Scholar
• THE BIP STUDY GROUP: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation (2000) 102(1):21-27.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. (1999) 341:410-418.
   PubMed Web of Science ®Google Scholar
• ROBINS SJ, COLLINS D, WITTES JT et al.; VETERANS AFFAIRS HIGH-DENSITY LIPOPROTEIN INTERVENTION TRIAL: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA (2001) 285(12):1585-1591.
   PubMed Web of Science ®Google Scholar
• ROBINS SJ, RUBINS HB, FAAS FH et al.; VETERANS AFFAIRS HDL INTERVENTION TRIAL (VA-HIT): Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care (2003) 26(5):1513-1517.
   PubMed Web of Science ®Google Scholar
• OTVOS JD, COLLINS D, FREEDMAN DS et al.: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation (2006) 113(12):1556-1563.
   PubMed Web of Science ®Google Scholar
• KEECH A, SIMES RJ, BARTER P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet (2005) 366(9500):1849-1861.
   PubMed Web of Science ®Google Scholar
• WHITNEY EJ, KRASUSKI RA, PERSONIUS BE et al.: A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann. Intern. Med. (2005) 142(2):95-104.
   PubMed Web of Science ®Google Scholar
• CARLSON L: Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258(2):94-114.
   PubMed Web of Science ®Google Scholar
• GUYTON JR, BLAZING MA, HAGAR J et al.: Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch. Intern. Med. (2000) 160(8):1177-1184.
   PubMedGoogle Scholar
• ASHEN MD, BLUMENTHAL RS: Low HDL cholesterol levels. N. Engl. J. Med. (2005) 353(12):1252-1260.
   PubMed Web of Science ®Google Scholar
• MCKENNEY J: New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. (2004) 164(7):697-705.
   PubMed Web of Science ®Google Scholar
• CHAPMAN J: Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol. Ther. (2006) 111:893-908.
   PubMed Web of Science ®Google Scholar
• RUBIC T, TROTTMANN, M, LORENZ RL: Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol. (2004) 67:411-419.
   PubMed Web of Science ®Google Scholar
• FY J, KAMANNA VS, KASHYAP ML: Niacin decreases removal of high density lipoprotein A-1 but not cholesterol ester by hep G2 cells: implications for reverse cholesterol transport.
   Google Scholar
• GARG A, GRUNDY SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA (1990) 264:723-726.
   PubMed Web of Science ®Google Scholar
• ELAM MB, HUNNINGHAKE DB, DAVIS KB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA (2000) 284(10):1263-1270.
   PubMed Web of Science ®Google Scholar
• CANNER PL, FURBERG CD, TERRIN ML, MCGOVERN ME: Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol. (2005) 95(2):254-257.
   PubMed Web of Science ®Google Scholar
• BENYO Z, GILLE A, BENNETT CL, CLAUSEN BE, OFFERMANNS S: Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol. Pharmacol. (2006) 70(6):1844-1849.
   PubMed Web of Science ®Google Scholar
• CANNER PL, BERGE KG, WENGER NK et al.: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. (1986) 8:1245-1255.
   PubMed Web of Science ®Google Scholar
• CARLSON LA, ROSENHAMER G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. (1988) 223:405-418.
   PubMed Web of Science ®Google Scholar
• BROWN BG, ZHAO XQ, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. (2001) 345:1583-1592.
   PubMed Web of Science ®Google Scholar
• TAYLOR AJ, SULLENBERGER LE, LEE HJ, LEE JK, GRACE KA: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation (2004) 110(23):3512-3517.
   PubMed Web of Science ®Google Scholar
• TAYLOR AJ, LEE HJ, SULLENBERGER LE: The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. (2006) 22(11):2243-2250.
   PubMed Web of Science ®Google Scholar
• APPEL LJ, BRANDS MW, DANIELS SR et al.: Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension (2006) 47:296-308.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342:145-153.
   PubMed Web of Science ®Google Scholar
• WANNAMETHEE SG, LOWE GD, WHINCUP PH et al.: Physical activity and hemostatic and inflammatory variables in elderly men. Circulation (2002) 105:1785-1790.
   PubMed Web of Science ®Google Scholar
• LEE KW, LIP GY: Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch. Intern. Med. (2003) 163(19):2368-2392.
   PubMed Web of Science ®Google Scholar
• PEARSON T, BLAIR S, DANIELS S et al.: AHA guidelines for primary prevention of cardiovascular diseases and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation (2002) 106:388-391.
   PubMed Web of Science ®Google Scholar
• SMITH SC, ALLEN J, BLAIR SN et al.: AHA/ACC; National heart, lung, and blood institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National heart, lung, and blood institute. Circulation (2006) 113(19):2363-2372.
   PubMed Web of Science ®Google Scholar
• VETTOR R, SERRA R, FABRIS R et al.: Effect of sibutramine on weight management and metabolic control in Type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care (2005) 28:942.
   PubMed Web of Science ®Google Scholar
• TONSTAD S, POMETTA D, ERKELENS DW et al.: The effects of gastrointestinal lipase inhibitor orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidemia. Eur. J. Clin. Pharmacol. (1994) 46:405.
   PubMed Web of Science ®Google Scholar
• HOLLANDER P, ELBEIN SC, HIRSCH IB et al.: Role of orlistat in the treatment of obese patients with Type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care (1998) 21:1288.
   PubMed Web of Science ®Google Scholar
• LARA MD, KOTHARI SN, SUGERMAN HJ: Surgical management of obesity: a review of the evidence relating to the health benefits and risks. Treat. Endocrinol. (2005) 4(1):55-64.
   PubMedGoogle Scholar
• VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe. Lancet (2005) 365:1389-1397.
   PubMed Web of Science ®Google Scholar
• DEPRES JP, GOLAY A, SJOSTROM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353:2121-2134.
   PubMed Web of Science ®Google Scholar
• PI-SUNYER, ARONNE LJ, HASSAN M, HESHMATI HM, DEVIN J, ROSENSTOCK J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA (2006) 295:761-775.
   PubMed Web of Science ®Google Scholar
• SPRECHLER DL, MASSIEN C, PEARCE G et al.: Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor d agonist. Arterioscler. Thromb. Vasc. Biol. (2007) 27:359-365.
   PubMed Web of Science ®Google Scholar
• FURNSINN C, WILLSON TM, BRUNMAIR B: Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia (2007) 50:8-17.
   PubMed Web of Science ®Google Scholar
• GRAHAM TL, MOOKHERJEE C, SUCKLING KE et al.: The PPAR δ agonist GW0742X reduces atherosclerosis in LDLR-/- mice. Atherosclerosis (2005) 181:29-37.
   PubMed Web of Science ®Google Scholar
• HERMANOWSKI-VOSATKA A, BALKOVEC JM, CHENG K et al.: 11 β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. (2005) 202:517-515.
   PubMed Web of Science ®Google Scholar